The progress of combined therapy of omalizumab and allergen immunotherapy in children with moderate to severe allergic asthma
10.3760/cma.j.issn.1673-4408.2023.05.004
- VernacularTitle:奥马珠单抗联合变应原免疫治疗在儿童中重度过敏性哮喘中的研究进展
- Author:
Wenxin SHEN
1
;
Yunxiao SHANG
;
Lishen SHAN
Author Information
1. 中国医科大学附属盛京医院小儿呼吸内科，沈阳 110004
- Keywords:
Children;
Moderate to severe allergic asthma;
Omalizumab;
Allergen immunotherapy;
Combined therapy
- From:
International Journal of Pediatrics
2023;50(5):306-311
- CountryChina
- Language:Chinese
-
Abstract:
Allergen immunotherapy(AIT)is considered the treatment capable of modifying the natural history of allergic respiratory disorders.The adverse reactions associated with AIT limit its clinical use in moderate to severe allergic asthma.Omalizumab is currently approved for the treatment of allergic asthma, chronic spontaneous urticaria, allergic rhinitis and other allergic diseases.A few trials have demonstrated the clinical efficacy of AIT and omalizumab combination therapy in children with moderate to severe allergic asthma.This review summarizes the research progress, mechanisma and application of omalizumab combined with AIT in children with moderate to severe allergic asthma.
